LILIAN OGUJIOFOR: Open Payments
NPI 1255635058 · LANSDOWNE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,807 in 74 payments from 17 companies in 2025. Trend: 2023 $1,766 · 2024 $2,705 · 2025 $3,807
Food & beverage: $3,807
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $742 |
| Vanda Pharmaceuticals Inc. | 7 | $565 |
| Otsuka America Pharmaceutical, Inc. | 10 | $483 |
| ABBVIE INC. | 20 | $381 |
| Neurocrine BioSciences, Inc. | 4 | $290 |
| Axsome Therapeutics, Inc. | 3 | $262 |
| Janssen Pharmaceuticals, Inc | 5 | $251 |
| Teva Pharmaceuticals USA, Inc. | 2 | $244 |
| E.R. Squibb & Sons, L.L.C. | 3 | $227 |
| Alkermes, Inc. | 2 | $148 |
Products named: CAPLYTA, FANAPT, REXULTI, VRAYLAR, INGREZZA, Auvelity, AUSTEDO XR, COBENFY.
Industry payments across PA — which companies pay providers there.
